Practice Essentials

Leptospirosis is an infectious disease of humans and animals that is caused by pathogenic spirochetes of the genus Leptospira (see the image below). It is considered the most common zoonosis in the world and is associated with rodents in settings of poor sanitation, agricultural occupations, and increasingly "adventure" sports or races involving fresh water, mud, or soil exposure.

View Image

A scanning electron micrograph depicting Leptospira atop a 0.1-µm polycarbonate filter. (This image is in the public domain and thus free of any copyr....

Signs and symptoms

Leptospirosis ranges in severity from a mild illness suggesting a viral infection to a multisystemic syndrome with unique features. It is characterized by sudden onset of the following:

More severe disease manifests as icteric leptospirosis, also known as Weil disease, with the following features:

See Clinical Presentation for more detail. 


Laboratory studies used to screen for the diagnosis of leptospirosis include the following:

Laboratory studies used to confirm the diagnosis of leptospirosis include the following:

Studies to determine the extent of organ involvement and severity of complications may include the following, depending on the clinical presentation:

See Workup for more detail.


Antibiotic therapy in the treatment of mild leptospirosis is typically unnecessary, since it is often self-limited, and most cases resolve without medical attention. Oral antibiotics shorten the course of illness and, perhaps most importantly, reduce and shorten urinary excretion of leptospires. Prophylaxis may be used in the setting of epidemics. If used, antibiotic treatment may include the following:

Antibiotics for leptospirosis requiring hospitalization include the following:

Patients with severe cases of leptospirosis also require supportive therapy and careful management of renal, hepatic, hematologic, and central nervous system complications. If renal failure ensues, early initiation of hemodialysis or peritoneal dialysis may reduce mortality by nearly two-thirds. Additional supportive care may include inotropic agents, diuretics, or ophthalmic drops.

See Treatment and Medication for more detail.


Leptospirosis is an infectious disease of humans and animals that is caused by pathogenic spirochetes of the genus Leptospira. It is considered the most common zoonosis in the world.[1] Leptospirosis is distributed worldwide (sparing the polar regions) but is most common in the tropics.

Leptospirosis has been recognized as a re-emerging infectious disease among animals and humans[2] and has the potential to become even more prevalent with advancing climate change and related trends.[3] By 2100, various climate models project that global temperatures will rise by 2°F to 11.5°F, depending on trends in future greenhouse gas emissions.[4]

Leptospira species infect a wide range of animals, including mammals, birds, amphibians, and reptiles. Humans are rarely chronic carriers and are therefore considered accidental hosts. The organism is typically transmitted via exposure of mucous membranes or abraded skin to the body fluid of an acutely infected animal or by exposure to soil or fresh water contaminated with the urine of an animal that is a chronic carrier.

Occupational exposure probably accounts for 30-50% of human cases of leptospirosis. The main occupational groups at risk include farm workers, veterinarians, pet shop owners, field agricultural workers, abattoir workers, plumbers, meat handlers and slaughterhouse workers, coal miners, workers in the fishing industry, military troops, milkers, and sewer workers.

Although leptospirosis continues to be predominantly an occupational disease, in recent decades it has also increasingly been recognized as a disease of recreation. The disease may be acquired during "adventure" travel or sporting events that involve fresh water or hiking (eg, "mud runs").[5, 6, 7, 8] The exotic-pet trade further increases the likelihood of transmission.

Widespread flooding may lead to epidemic spread of leptospirosis in large populations.[9] Flooding on a smaller scale may also lead to individuals contracting the disease.[10] Urban dwellers in economically deprived areas may contract the disease through exposure to rat urine.[11]

In 90% of cases, leptospirosis manifests as an acute febrile illness with a biphasic course and an excellent prognosis. Nonspecific signs and symptoms of leptospirosis (eg, fever, headache, nausea, vomiting) are often confused with viral illness.

In 10% of cases, the presentation is more dramatic, and the infection has an overall case fatality rate of 5%-10%. Known as Weil disease or icteric leptospirosis, the classic definition of this form of leptospirosis includes fever, jaundice, renal failure, and hemorrhage. Other organ systems (ie, pulmonary system, cardiac system, central nervous system) are also frequently involved. Risk factors associated with higher mortality risk include old age, alteration of mental status, and pulmonary alveolar hemorrhage. (See Clinical Presentation.)

Treatment of leptospirosis should be started as soon as possible. Treatment is begun empirically in patients with a plausible exposure history and compatible symptoms, as culture times for Leptospira are long and recovery rates are low. The criterion standard for serologic identification of leptospires, microscopic agglutination testing (MAT), is available only at reference laboratories. Paired acute and convalescent serum specimens can provide delayed confirmation of the diagnosis.

In uncomplicated infections that do not require hospitalization, oral doxycycline has been shown to decrease duration of fever and most symptoms. In hospitalized patients, intravenous penicillin G has been the treatment of choice. Patients with severe leptospirosis (Weil disease) require supportive therapy and careful management of renal, hepatic, hematologic, and central nervous system complications. (See Treatment.)

Historical background

In ancient China, a disease that was certainly leptospirosis was recognized as an occupational hazard of rice harvesters. In Japan, leptospirosis was called akiyami, or autumn fever, a term still used for this disease.[12]

In the West, leptospirosis was described by Larrey in 1812 as fièvre jaune among Napoleon's troops at the siege of Cairo. The disease was initially believed to be related to the plague but not as contagious. Throughout the remainder of the 19th century, leptospirosis was known in Europe as bilious typhoid.

Leptospirosis was recognized as an occupational disease of sewer workers in 1883. In 1886, Adolph Weil published his historic paper describing the most severe form of leptospirosis that would be later known as Weil disease. Weil described the clinical manifestations in 4 men who had severe jaundice, fever, and hemorrhage with renal involvement.[13]

In 1907, Stimson used special staining techniques in the postmortem examination of a kidney from a person with Weil disease and found a spiral organism with hooked ends, which was named Spirochaeta interrogans because its shape resembled that of a question mark. Inada et al identified the causal agent of infectious jaundice in Japan in 1916, naming the organism Spirochaeta icterohaemorrhagiae.[13]


Leptospires are thin, coiled, gram-negative, aerobic organisms 6-20 µm in length (see the image below). They are motile, with hooked ends and paired axial flagella (one on each end), enabling them to burrow into tissue. Motion is marked by continual spinning on the long axis. They are unique among the spirochetes in that they can be isolated on artificial media.

View Image

A scanning electron micrograph depicting Leptospira atop a 0.1-µm polycarbonate filter. (This image is in the public domain and thus free of any copyr....

Leptospires belong to the order Spirochaetales and the family Leptospiraceae. Traditionally, the organisms are classified based on antigenic differences in the lipopolysaccharide envelopes that surround the cell wall. Serologic detection of these differences, therefore, is based on identifying serovars within each species. Based on this system, the genus Leptospira contains two species: the pathogenic Leptospira interrogans, with at least 218 serovars; and the nonpathogenic, free-living, saprophytic Leptospira biflexa, which has at least 60 serovars.

Current studies that classify the organisms based on DNA relatedness identify at least 7 pathogenic species of leptospires. However, organisms that are identical serologically may be different genetically, and organisms with the same genetic makeup may differ serologically. Therefore, some authors feel that the traditional serologic system is the most useful from a diagnostic and epidemiologic standpoint.

Animal reservoirs

Most leptospiral serovars have a primary reservoir in wild mammals, which continually reinfect domestic populations. The organism affects at least 160 mammalian species and has been recovered from rats, swine, dogs, cats, raccoons, cattle, mongooses, and bandicoots.[14, 15] The most important reservoirs are rodents, and rats are the most common source worldwide. In the United States, important leptospiral sources include dogs, livestock, rodents, wild animals, and cats.

Many serovars are associated with particular animals. For example, L pomona and L interrogans are seen in cattle and pigs; L grippotyphosa is seen in cattle, sheep, goats, and voles; L ballum and L icterohaemorrhagiae are associated with rats and mice; and L canicola is associated with dogs. Other important serotypes include Lautumnalis, Lhebdomidis, and Laustralis. Leptospiral species' and serogroups' host animals vary from region to region. Individual animals may carry several serovars.

Leptospirosis in animals is often subclinical. Leptospires may persist for long periods in the renal tubules of animals by establishing a symbiotic relationship with no evidence of disease or pathological changes in the kidney. As a result, animals that serve as reservoirs of host-adapted serovars can shed high concentrations of the organism in their urine without showing clinical evidence of disease.

This leptospiruria in animals often occurs for months after the initial infection. Leptospiruria also has been found to occur in healthy immunized dogs. Leptospiruria in humans is more transient, rarely lasting more than 60 days. Humans and nonadapted animals are incidental hosts. With rare exceptions, man represents a dead end in the chain of infection because person-to-person spread of the disease is rare.

Transmission and incubation

Urinary shedding of organisms from infected animals is the most important source of these bacterial pathogens. Contact with the organism via infected urine or urine-contaminated media results in human infection. Such media include contaminated water and food, as well as animal bedding, soil, mud, and aborted tissue. Under favorable conditions, leptospires can survive in fresh water for as many as 16 days and in soil for as many as 24 days.[16]

Leptospires are believed to enter the host through the following:

Virulent organisms in a susceptible host gain rapid access to the bloodstream through the lymphatics, resulting in leptospiremia and spread to all organs, but particularly the liver and kidney. The incubation period is usually 5-14 days but has been described from 72 hours to a month or more.

Pathologic effects

Although direct invasion of tissue may cause some pathologic effects, researchers note that the marked degree of multiorgan tissue injury appears inconsistent with the number of leptospires found on microscopic examination of tissue. Other mediators induced by the leptospire are the suspected causes of the disease's various manifestations. Research has suggested endotoxin, hemolysin, and lipase as possible sources of pathogenicity. However, the true mechanism of host tissue injury remains unclear and likely involves a complex set of interactions.

The most consistent pathologic finding in leptospirosis is vasculitis of capillaries, manifested by endothelial edema, necrosis, and lymphocytic infiltration. Capillary vasculitis is found in every affected organ system. The resulting loss of red blood cells and fluid through enlarged junctions and fenestrae, which cause secondary tissue injury, probably accounts for many of the clinical findings.

In the kidneys, leptospires migrate to the interstitium, renal tubules, and tubular lumen, causing interstitial nephritis and tubular necrosis. Capillary vasculitis is readily identified. Although the glomeruli are spared, the progression from normal renal function to decreased glomerular filtration rate to renal failure requiring dialysis can be rapid. Renal failure is usually due to tubular damage, but hypovolemia from dehydration and from altered capillary permeability can also contribute to renal failure.

Liver involvement is marked by centrilobular necrosis and Kupffer cell proliferation. Jaundice may occur as a result of hepatocellular dysfunction.

Pulmonary involvement is secondary to alveolar and interstitial vascular damage resulting in hemorrhage. This complication is considered to be the major cause of leptospirosis-associated death.

Cardiac lesions have been identified in postmortem examinations. In an autopsy series of fatal cases of leptospirosis in Mumbai, India in 2005, involvement of the cardiovascular system was found in 41 of 44 cases. Interstitial myocarditis was the predominant feature on histopathological examination. These authors suggested that leptospirosis be viewed as an infective systemic vasculitis.[18]

Hemorrhage, focal necrosis, and inflammatory infiltration have been documented within the adrenal gland. Although these complications do not appear clinically, some researchers speculate that adrenal insufficiency may mediate, in part, the final vascular collapse associated with fatal leptospirosis.

The skin is affected by epithelial vascular insult. Skeletal muscle involvement is secondary to edema, myofibril vacuolization, and vessel damage. Muscular microcirculation is impaired and capillary permeability is increased, with resultant fluid leakage and circulatory hypovolemia.

The damage to the vascular system as a whole can result in capillary leakage, hypovolemia, and shock. Patients with leptospirosis may develop disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), or thrombotic thrombocytopenic purpura (TTP). Thrombocytopenia indicates severe disease and should raise suspicion for a risk of bleeding.[19, 20]

If the host survives the acute infection, septicemia and multiplication of the organism persist until the development of opsonizing immunoglobulin in the plasma, followed by rapid immune clearance. Although the systemic immune response may eliminate the organism from the body, it may also lead to a symptomatic inflammatory reaction that can produce secondary end-organ injury.

Despite clearance from the blood, leptospires may remain in immunologically privileged sites, including the renal tubules, brain, and aqueous humor of the eye, for weeks to months. Persistent leptospires in the eye occasionally lead to chronic or recurrent uveitis. In humans, leptospires in the renal tubules and resulting leptospiruria rarely persist longer than 60 days.


Leptospirosis is caused by spiral bacteria that belong to the genus Leptospira, the family Leptospiraceae, and the order Spirochaetales. These spirochetes are finely coiled, thin, motile, obligate, slow-growing anaerobes.

The nomenclature system used to organize leptospires has been revised, making review of the literature often confusing. The traditional system divided the genus into 2 species: the pathogenic Leptospira interrogans and the nonpathogenic Leptospira biflexa. These species were divided further into serogroups, serovars, and strains based on shared antigens. L interrogans included more than 250 serovars.

The current classification system is based on DNA homology and recognizes the heterogeneity of the classic leptospires, dividing L interrogans and L biflexa into 20 named species.[21] Within these species, leptospires are further grouped by serogroups, serovars, and strains on the basis of microscopic agglutination testing (MAT).

Serologic grouping may, however, cross DNA-based species boundaries, and both pathogenic and nonpathogenic serovars may be found within the same species. Although certain species (eg, L interrogans) have a classic association with Weil disease, knowledge of the species type does not necessarily help predict disease severity.

Particular serovars may be associated with specific clinical manifestations. For example, a characteristic pretibial erythematous rash is seen in patients with L autumnalis infection, and gastrointestinal symptoms predominate in patients infected with L grippotyphosa.

Nevertheless, any leptospiral serovar can lead to the signs and symptoms seen with this disease. For example, jaundice occurs in 83% of patients with L icterohaemorrhagiae infection and in 30% of patients infected with L pomona. Aseptic meningitis commonly occurs in those infected with L pomona or L canicola.

Transmission of leptospires to humans typically occurs by invasion across mucosal surfaces or nonintact skin. Infection may occur via direct contact with infected animals or their tissues or urine or through contact with contaminated water and soil.


United States statistics

Leptospirosis, as a clinical entity, is underdiagnosed and underreported. From 1985-1994, the reported annual incidence ranged from 0.02-0.04 cases per 100,000 persons. In 1994, 38 leptospirosis cases were reported nationwide, and the Council of State and Territorial Epidemiologists recommended removing leptospirosis from the list of notifiable diseases.[22]

Because reliable diagnostic testing was not readily available and organized reporting had not resulted in implementation of methods to control the disease, many states stopped reporting leptospirosis. Nevertheless, numerous states, including Hawaii, continued to report. In 2013, leptospirosis was reinstated as a nationally notifiable disease.

In Hawaii, which reports the highest annual occurrence rate, 405 suspected cases of leptospirosis were reported between June 1998 and February 1999; 61 of those cases were confirmed.[23] Case numbers widely varied from island to island within the state. Incidence rates ranged from 2.3-40.2 cases per 100,000 persons, with the highest numbers of cases on Kauai and Hawaii.

These reported cases starkly contrast with the prevalence rates found under active surveillance.[24] Using active surveillance measures, Hawaiian researchers projected the state's true local incidence at approximately 128 cases per 100,000 persons. Major risk factors identified in Hawaii include the use of water catchment systems, wild pig hunting, and the presence of skin wounds.

An estimated 100-200 cases are identified annually in the United States, with about 50% of cases occurring in Hawaii. Endemic canine leptospirosis is becoming more common in the United States, and California has seen a re-emergence of disease since 2000. Over the past 20 years, epidemiology has begun to shift from primarily recreational water exposures to an increasing number of occupational exposures related to farm and agricultural activities.[25]

Although less dramatic and often unrecognized, people with no obvious risk factor have significantly higher background infection rates than reports often indicate. Approximately 30% of children in urban Detroit[26] and 16% of adults in Baltimore[27] demonstrated serologic evidence of past infection. The Detroit study also showed correlation between degree of rat infestation and seropositivity rates. This finding suggests rats are major, if not the most important, vectors for human leptospirosis in the mainland United States.

Leptospirosis has a seasonal incidence. Most cases occur during the rainy season in the tropics and during the late summer or early fall in Western countries, when the soil is moist and alkaline. The leptospires from infected animals survive best in fresh water, damp alkaline soil, vegetation, and mud with temperatures higher than 22°C.

International statistics

Leptospirosis is a ubiquitous disease found throughout the world. Specific serovars vary with locality. The incidence varies from sporadic in temperate zones to endemic in a few tropical countries. Up to 80% of individuals in tropical areas are estimated to have positive seroconversion rates, indicating either past or present infection. Although leptospirosis is generally associated with tropical countries and heavy rainfall, most cases actually occur in temperate climates, probably because of underreporting in some countries.

High-risk areas include the Caribbean islands, Central and South America, Southeast Asia, and the Pacific islands. Frequently, the disease gains public attention when outbreaks occur in association with natural disasters, such as flooding in Nicaragua in 1995[9] or among foreign travelers, as with extreme athletes competing in tropical rainforests.

Sexual and age-related differences in incidence

No evidence suggests that leptospirosis affects persons of various races, ages, or sexes differently. However, because occupational exposure constitutes a major risk for development of disease, a disproportionate number of working-aged males seem to be affected.

On the other hand, the rates may be different because some practitioners are more likely to look for and, hence, diagnose the disease in patients who have obvious risk factors. When population groups other than adult males are actively surveyed, their rates are higher than those previously reported.

In addition, outbreaks have been reported in which more than 40% of patients were younger than 15 years, a reversal of traditional prevalence rates. Potential explanations in such cases include childhood predilections to play with suspected vectors (eg, dogs) or indiscriminate contact with water. Active surveillance measures have detected leptospire antibodies in as many as 30% of children in some urban American populations.

Seasonal variation in incidence

Leptospirosis has a seasonal incidence. Most cases occur during the rainy season in the tropics and during the late summer or early fall in Western countries, as leptospires survive best in fresh water, damp alkaline soil, vegetation, and mud with temperatures higher than 22°C.

Seasonal outbreaks associated with changes in local water levels have been described. Flood conditions increase risk of exposure to the population at large, and drought causes leptospire concentrations to peak in isolated pools.[28, 29]

Seasonal variation also correlates with participation in activities that increase exposure to leptospires. For example, outbreaks have been reported in triathlon athletes and white-water rafters.[6, 7, 8]


The mild form of leptospirosis is rarely fatal, and an estimated 90% of cases fall into this category. The mortality rate in severe leptospirosis averages approximately 10%, but has been described as ranging from 5-40%. Elderly and immunocompromised people are at the highest risk of mortality overall. Most deaths occur from renal failure, massive hemorrhage, or acute respiratory distress syndrome (ARDS).

The incidence of pulmonary involvement has increased over the past few years, affecting up to 70% patients. Pulmonary involvement has emerged as a serious cause of mortality, becoming the main cause of leptospirosis-associated death in some countries.[30, 31]

Leptospirosis occurring during pregnancy is ominous. In a review of 16 cases, spontaneous abortion was likely during the first 2 trimesters.[32] When disease occurred in the third trimester, a third of pregnancies ended in abortion or perinatal death.

In general, survivors of leptospirosis experience little long-term morbidity, regardless of disease severity. Hepatic and renal functions return to normal, despite severe dysfunction during acute illness, even among patients who required dialysis.

Approximately a third of patients with documented aseptic meningitis may continue to complain of periodic headaches of varying severities. Patients who have had leptospiral uveitis may experience persistent visual acuity loss (caused by lens pigmentation following anterior uveitis) and blurry vision (associated with keratic precipitates in the anterior chamber).

Patient Education

Travelers and participants in "adventure racing" or other freshwater sports who may be hiking and may otherwise be exposed to fresh water, soil, mud, and vegetation are at higher risk, especially those older than 60 years or those who are immunosuppressed. These individuals in particular should seek information concerning the risk of leptospirosis (and other infectious diseases) at their destinations before they travel and take appropriate precautions.

Patients should be advised to do the following:


A good clinical history is often the key to accurate diagnosis in leptospirosis. Important features include a plausible exposure history and a clinical picture consistent with the disease.

The exposure history may reveal direct contact with body fluids or organs of infected animals, or indirectly (eg, via contaminated soil or water). Direct exposure often occurs in occupational cases, while indirect exposure is more typical of cases contracted during travel or recreational activities rivers (eg, white-water rafting). Onset of clinical illness occurs abruptly, after an incubation period of 2-30 days (typically 5-14 d).

Expert consensus is that leptospirosis occurs as two recognizable clinical syndromes: anicteric and icteric (the existence of a third syndrome of asymptomatic infection is more controversial). Anicteric leptospirosis is a self-limited, mild flulike illness. Icteric leptospirosis, also known as Weil disease, is a severe illness characterized by multiorgan involvement or even failure.

Two distinct phases of illness are observed in the mild form: the septicemic (acute) phase and the immune (delayed) phase. In icteric leptospirosis, the 2 phases of illness are often continuous and indistinguishable. At disease onset, clinically predicting the severity of disease is not possible.

An acute illness follows infection with any serovar of leptospirosis. Most of the following signs and symptoms may develop in varying degrees:

Despite reports of fever as a cardinal symptom, research by the Hawaii Department of Health found that the presence of fever varied.[24, 33] In serologically confirmed cases, 5% of patients gave no history of fever, and 55% were afebrile at the time of presentation. Myalgias and headache were universally reported at the time of presentation and were the chief complaint in 25% of patients.

The natural course of leptospirosis falls into 2 distinct phases. The acute phase of illness lasts 5-7 days and is followed by a 1-3 day period of improvement in which the temperature curve falls and the patient may become afebrile and relatively asymptomatic. Subsequently, leptospirosis either regresses to a relatively asymptomatic illness or progresses to a more severe illness.

Recurrence of fever indicates the onset of the second, immune stage. Nonspecific symptoms, such as fever and myalgia, may be less severe than in the first stage and last a few days to a few weeks. Many patients (77%) experience headache that is intense and poorly controlled by analgesics; this often heralds the onset of meningitis.

Aseptic meningitis is the most important clinical syndrome observed in the immune anicteric stage. Meningeal symptoms develop in 50% of patients. Cranial nerve palsies, peripheral facial palsy,[34] encephalitis, and changes in consciousness are less common. Mild delirium may also be seen. Meningitis usually lasts a few days but occasionally lasts 1-2 weeks. Death is extremely rare in anicteric cases.

Abdominal pain with diarrhea or constipation (30%), hepatosplenomegaly, nausea, vomiting, and anorexia are also seen. Acalculous cholecystitis may be seen rarely but is clinically significant.[35]

Uveitis (2-10%) can develop early or late in the disease and has been reported to occur as late as one year after initial illness. Iridocyclitis and chorioretinitis are other late complications that may persist for years. These symptoms first manifest 3 weeks to 1 month after exposure. Subconjunctival hemorrhage is the most common ocular complication of leptospirosis, occurring in as many as 92% of patients.

Renal manifestations include hematuria. Oliguric or anuric acute tubular necrosis may occur during the second week due to hypovolemia and decreased renal perfusion.

Weil syndrome, the severe form of leptospirosis, primarily manifests as profound jaundice, renal dysfunction, hepatic necrosis, pulmonary dysfunction, and hemorrhagic diathesis. Pulmonary manifestations include cough, dyspnea, chest pain, bloodstained sputum, hemoptysis, and respiratory failure.

Physical Examination

The physical examination findings differ depending on the severity of disease and the time from onset of symptoms. Patients may appear mildly ill or toxic. Early in the disease, temperatures as high as 40°C and tachycardia are common. Hypotension, oliguria, and abnormal chest auscultation findings at presentation may portend severe illness. When fever is severe and prolonged, hypotension and shock due to volume depletion may also occur. The fever typically subsides within 7 days.

Early in the disease, the skin is warm and flushed. Additional skin findings include a transient petechial eruption that can involve the palate. Later in severe disease, jaundice and purpura can develop. The classic ocular finding of conjunctival suffusion occurs early irrespective of disease severity. Conjunctival suffusion is characterized by redness of the conjunctiva that resembles conjunctivitis but that does not involve inflammatory exudates.

Uveitis is a common feature following acute leptospirosis. However, patients who receive antibiotics during the acute phase of illness may develop only mild uveitis.[36]

Muscle tenderness can occur with the myositis of early infection. This can be particularly prominent in the paraspinal and calf muscles but can involve any muscle.

Neurologic examination can reveal signs of meningitis, including neck stiffness and rigidity and photophobia. Early in the disease, the stiffness on neck examination can be confused as muscular in origin; however, this symptom may actually represent early meningismus.

Lung examination results may be normal in early or mild illness. In severe illness, signs of consolidation due to alveolar hemorrhage may be found. In patients with cardiac-related pulmonary edema, rales and wheezes can be heard.

Abdominal examination may reveal liver enlargement and tenderness due to hepatitis. Acalculous cholecystitis, which may be suggested by a positive Murphy sign, is a finding of profound systemic illness. Pancreatitis has also been described in severe cases.[37, 38, 39] Heme-positive stool and even gross blood can be found on rectal examination in patients with DIC and bleeding.

In severe disease, delirium may develop either as a consequence of shock or independent of it. Delirium may be an early finding in severe disease. Late in disease and into convalescence, prolonged mental symptoms may persist, including depression, anxiety, irritability, psychosis, and even dementia.

Rash may present as a macular or maculopapular eruption with erythematous, urticarial, petechial, or desquamative lesions. Adenopathy may be noted.


The infection may progress to severe systemic inflammatory syndrome with hemorrhagic features. Findings of disseminated intravascular coagulation may occur with bleeding.

The onset of mental status alterations indicates progression to parenchymal involvement of the cerebral cortex with meningo-encephalitis, heralding a high mortality risk.

Severe and diffuse alveolar hemorrhage with massive hemoptysis can occur in the absence of typical Weil disease.

Myocarditis may occur in severe disease. All of the physical findings of biventricular heart failure can be found, including elevated jugular venous pulsations; a new S3 gallop; and dysrhythmias, including atrial fibrillation, heart blocks of varying severity, and ventricular ectopy.

Acalculous cholecystitis is a finding of profound systemic illness. Pancreatitis has also been described in severe cases.[37, 38, 39]

Uveitis, iridocyclitis, and chorioretinitis may occur late into illness and may persist for years.

Approach Considerations

Leptospires grow slowly in culture, and recovery rates are low. Serologic tests are available only in specialized laboratories, and the sensitivity of acute serologic tests is low. Consequently, those tests should not be the basis on which treatment is initiated. In a patient with compatible symptoms and a plausible exposure history, empiric therapy should be started.

Laboratory studies are used for two purposes: to confirm the diagnosis and to determine the extent of organ involvement and severity of complications. Laboratory confirmation of leptospirosis can be accomplished through isolation of the pathogen or by serologic testing.

Isolation of the leptospires from human tissue or body fluids is the criterion standard, but culture is not routinely available; thus, molecular assays such as DNA PCR are more commonly used, if available. Consultation with the local microbiology laboratory is essential, because processing requires specialized techniques. Urine is the most reliable body fluid to study because the urine contains leptospires from the onset of clinical symptoms until at least the third week of infection.

Other body fluids contain the organism, but the window of opportunity to isolate them is shorter. Blood and CSF may produce positive PCR or cultures during the first 7-10 days of symptoms.

Tissues (ie, liver, muscle, kidney, skin, eyes) are also sources of identification of the leptospires but are obviously more complicated to acquire.

Most often, paired acute and convalescent serum specimens are used to confirm the diagnosis. Again, this is a delayed means of confirmation because the acute sera are collected 1-2 weeks after onset of symptoms, and the convalescent sera are collected 2 weeks afterward.

Antileptospire antibodies in these samples are detected using the microscopic agglutination test (MAT). The Centers for Disease Control and Prevention (CDC) laboratory in Atlanta, Georgia, performs the MAT using 23 leptospire antigens. A 4-fold rise in MAT titer between acute and convalescent sera with any of these antigens confirms the diagnosis of leptospirosis.

Faster laboratory methods may strongly suggest the diagnosis of leptospirosis, but they may be no more readily available than the CDC laboratory in Atlanta. A single MAT titer of 1:200 on any sera or identification of spirochetes on dark-field microscopy, when accompanied by the appropriate clinical scenario, is strongly suggestive.

In suspected leptospirosis, further laboratory studies should be routinely performed to determine the extent and severity of organ involvement after the acute phase of illness. A complete blood cell count (CBC) is necessary. Findings on general laboratory studies are as follows:

On urinalysis, proteinuria may be present. Leukocytes, erythrocytes, hyaline casts, and granular casts may be present in the urinary sediment.

Analysis of the CSF is useful only in excluding other causes of bacterial meningitis. When the CNS becomes involved in leptospirosis, polymorphonuclear leukocytes initially predominate and are later replaced by monocytes. CSF protein may be normal or elevated, whereas glucose levels remain normal. CSF pressure is normal, but a lumbar puncture can relieve the headache. Leptospires are routinely isolated from the CSF, but this finding does not change management of the disease.

Imaging studies are useful in determining the extent and severity of organ involvement. This may include chest radiography to evaluate lung disease and biliary tract ultrasonography in suspected acalculous cholecystitis.

Electrocardiographic (ECG) abnormalities are common during the leptospiremic phase of Weil syndrome. In severe cases, congestive heart failure and cardiogenic shock may occur.


Isolating the organism by culture allows definitive diagnosis. Leptospires remain viable in anticoagulated blood for as long as 11 days; hence, specimens can be mailed to a reference laboratory for culture. The infecting serovar can be isolated only by culture.

Blood cultures may be negative if drawn too early or too late. Leptospires may not be detected in the blood until 4 days after the onset of symptoms (7-14 d after exposure). Once the immune system is activated, blood cultures may again become negative. Leptospires may be isolated from the cerebrospinal fluid (CSF) within the first 10 days.

Leptospires may be isolated from the urine for several weeks after the initial infection. In some patients, urine cultures may remain positive for months or years after the onset of illness. Positive urine cultures may take as long as 8 weeks to grow.

Microscopic Agglutination Testing

Microscopic agglutination testing (MAT) uses a battery of antigens taken from common (frequently locally endemic) leptospire serovars. MAT is available only at reference laboratories, such as the Centers for Disease Control and Prevention (CDC).

In a patient with clinical findings consistent with the disease, a single titer exceeding 1:200 or serial titers exceeding 1:100 suggest leptospirosis; however, neither is diagnostic. A 4-fold rise in titer between acute and convalescent specimens is considered a positive result. The antibody response does not reach detectable levels until the second week of illness, and it can be affected by treatment.

False-negative MAT findings may result from testing a single specimen obtained before the immune phase of disease. Test accuracy is also affected by appropriate selection of antigens for the battery, necessitating discussion with the laboratory about which serovars are suspected or predominate in the region where the case originated. False-positive MAT results may occur with cases of Legionella infection, Lyme disease, and syphilis.

Other Tests

Screening tests for leptospirosis, which are easy to perform and provide results relatively rapidly, include the macroscopic slide agglutination test, the Patoc-slide agglutination test, the microcapsule agglutination test, latex agglutination tests, dipstick tests, and the indirect hemagglutination test. Confirmation of screening test results (positive or negative) is advisable, however, preferably with MAT.[40]

An immunoglobulin M (IgM) enzyme-linked immunoabsorbent assay (ELISA) has been developed. The ELISA uses a broadly reactive antigen and is a standard serologic procedure, as is the MAT.[41] Because it detects IgM, it may be useful for diagnosis of new infections within 3-5 days. Positive results should be referred for confirmatory testing.

Nucleic acid amplification (polymerase chain reaction [PCR])–based techniques have been developed to diagnose leptospirosis. PCR can confirm the diagnosis rapidly during the early phase of the disease, when leptospires may be present and before antibody titers are detectable, but it requires adequate infrastructure such as appropriate equipment, laboratory space, and skilled personnel. In addition, PCR-based techniques are unable to identify the infecting serovar, which reduce their epidemiologic and public health value.

Dark-field examination of blood or urine has been used to identify leptospires. However, this technique cannot be recommended, as it frequently leads to misdiagnosis.

Chest Radiography

The most common abnormality on chest radiography is bilateral diffuse airspace disease. Chest radiography may also reveal cardiomegaly and pulmonary edema due to myocarditis. In patients with alveolar hemorrhage due to pulmonary capillaritis, the lung parenchyma may contain multiple patchy infiltrates.

Histologic Findings

Shortly after inoculation and during the incubation period, leptospires actively replicate in the liver. The leptospires then disseminate throughout the body and infect multiple tissues.

Silver staining and immunofluorescence can identify leptospires in the liver, spleen, kidney, CNS, muscles, and heart. During the acute phase of leptospirosis, histology reveals these organisms without much inflammatory infiltrate. In addition to the finding of leptospires during histologic examination, the pathologic effects of leptospiral toxins are also apparent. See the image below.

View Image

Silver stain, liver, fatal human leptospirosis. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Cente....

Leptospirosis may be seen as an infective systemic vasculitis.[18] Leptospiral toxins break down endothelial cell membranes of capillaries. This toxin-mediated process allows for extravasation of blood and leptospires from blood vessels into the supported parenchyma. Secondarily, because the capillaries are no longer functional, ischemia and cell death can occur. Later in infection, mononuclear cells predominate in the areas of this focal cell necrosis.

Leptospires can be identified in immunologically privileged sites, such as renal tubules, CNS, and the anterior chamber of the eyes, for weeks to months after the initial infection. In nonhuman animals, the intended hosts of infection, the leptospires establish residence in these immunologically privileged sites. Provided that the animal survives the initial infection, a chronic carrier state is then established, and histology reveals leptospires at these sites for years after initial infection.

Approach Considerations

Antimicrobial therapy is indicated for the severe form of leptospirosis, but its use is controversial for the mild form of leptospirosis. A Cochrane Review found insufficient evidence to advocate for or against the use of antibiotics in the therapy for leptospirosis.[42]

If antibiotics are used, they should be initiated as soon as the diagnosis of leptospirosis is considered and should be continued for a full course despite initial serologic results, because most patients are diagnosed only through acute and convalescent testing. Early treatment has been shown to offer the best clinical outcomes; results from controlled studies of treatment during the immune phase have yielded mixed results.[43, 44]

Mild leptospirosis is treated with doxycycline, ampicillin, or amoxicillin. For severe leptospirosis, intravenous penicillin G has long been the drug of choice, although the third-generation cephalosporins cefotaxime and ceftriaxone have become widely used. Alternative regimens are ampicillin, amoxicillin, or erythromycin. Several other antibiotics may be useful—for example, broth microdilution testing has shown sensitivity to macrolides, fluoroquinolones, and carbapenems[45] —but clinical experience with these agents is more limited.

Severe cases of leptospirosis can affect any organ system and can lead to multiorgan failure. Supportive therapy and careful management of renal, hepatic, hematologic, and central nervous system complications are important.

Patients should be managed in a monitored setting because their condition can rapidly progress to cardiovascular collapse and shock. Access to mechanical ventilation and airway protection should be available in the event of respiratory compromise. Continuous cardiac monitoring should be attained; arrhythmias, including ventricular tachycardia and premature ventricular contractions, as well as atrial fibrillation, flutter, and tachycardia, can occur.

Renal function should be evaluated carefully and dialysis considered in cases of renal failure. In most cases, the renal damage is reversible if the patient survives the acute illness. Early initiation of hemodialysis or peritoneal dialysis considerably reduces mortality risk. A few cases in the literature have reported that plasma exchange, corticosteroids, and intravenous immunoglobulin may be beneficial in selected patients in whom conventional therapy does not elicit a response.[46, 47, 48]

Corticosteroid therapy is controversial. A 2014 review suggests lack of benefit and possible increased risk of nosocomial infection.[49] As with severity of illness, response may vary depending on host immune factors or the particular virulence of the leptospire. Treatment with high-dose pulsed methylprednisolone (30 mg/kg/d, not to exceed 1500 mg) has been used successfully to treat patients with leptospiral renal failure without dialysis. This approach may have be beneficial in resource-poor areas where dialysis is unavailable and would involve lengthy medical transport. The use of renal-dose dopamine in conjunction with steroids or diuretics has also been described.[23]

Pulse-dose steroids may also play a role early in the management of severe pulmonary disease.[50, 47] Patients with Weil syndrome may need transfusions of whole blood, platelets, or both. Ophthalmic drops of mydriatics and corticosteroids have been used for relief of ocular symptoms.[51]

Patients with severe disease should remain hospitalized until adequate resolution of organ failure and clinical infection. Outpatient follow-up may include an assessment of renal function to ensure ongoing reversal of any damage. A cardiac assessment may be indicated in patients with symptoms suggestive of heart involvement.

Diet and Activity

In mild cases, patients should be encouraged to maintain adequate fluid intake to avoid volume depletion. In more severe cases, diets appropriate for the clinical picture should be ordered (eg, electrolyte and protein restriction in cases of renal insufficiency). Patients with hypotension or clinical shock should not be fed enterally until adequate perfusion is restored.

Patients with severe disease should be placed on bed rest until adequately resuscitated and treated. Those with mild disease can pursue activity as tolerated.


Transfer to a facility with an appropriate level of care should be considered in patients with severe disease. Leptospirosis has a regional epidemiology with high incidence of cases in remote regions that offer limited medical care. Although transporting patients with severe disease to appropriate medical centers is preferred, military physicians who have treated patients from Western Pacific islands averted the need for transoceanic transport for dialysis by administering high-dose steroids.[38, 37]


In severe cases of leptospirosis, several specialty consultations may aid in proper patient management. An infectious disease specialist may assist in differentiating leptospirosis from diseases with similar presentations but that may have significantly different treatments. A nephrologist should be alerted early in the course because the need for dialysis may develop rapidly. If available, critical care specialists may be best prepared to manage patients with affected multiple systems.

For assistance with laboratory diagnosis, the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO) can aid the clinician in obtaining samples and ordering tests.


Prevention of leptospirosis is difficult because the organism has not been eradicated from wild animals, which constantly infect domestic animals. Important control measures include control of livestock infection with good sanitation, immunization, and proper veterinary care.

Preventing infected animals from urinating in waters where humans have contact, disinfecting contaminated work areas, providing worker education, practicing good personal hygiene, and using personal protective equipment (PPE) when handling infected animals or tissues are important actions for prevention of the disease. Examples of PPE include gloves and face shields for veterinarians and rubber boots for sewer workers and agricultural workers who wade in rodent urine-contaminated water.

Public health measures include investigation of cases in an effort to detect common source outbreaks and implementation of appropriate control measures to prevent further cases. Other public health measures include identification of contaminated water supplies, rodent control, prohibition of swimming in streams where risk of infection may be high, and informing people of risk when they are involved in recreational activities.

Vaccines are offered to high-risk workers in some European and Asian countries (eg, rice workers in Italy). Human vaccines are serovar specific and must be repeated yearly. They are associated with painful swelling, especially after revaccination. Vaccines are not used in the United States.

However, renal infection and persistent leptospiruria can occur in immunized dogs. Human infection has occurred from asymptomatic immunized dogs that still shed leptospires in their urine. Also, these animal vaccines are serovar specific and thus are useful only where one or a few serovars are present. Hence, the vaccine given should contain the serovars known to be prevalent in the area.

Doxycycline, in the dose of 200 mg every week, has demonstrated efficacy of 95% against leptospirosis and may help prevent the disease in exposed adults.[52, 53] This regimen is recommended for those with short-term exposure and is not for repeated or long-term exposure. The role of prophylaxis in children has not been adequately studied.

Medication Summary

Treatment for leptospirosis consists of empiric antibiotic therapy. In general, antibiotic therapy should be effective against leptospirosis and against the other pathogens considered in the differential diagnoses. If renal failure ensues, corticosteroids may be considered. Additional supportive care may include inotropic agents, diuretics, or ophthalmic drops. Currently, no human vaccine against leptospirosis is available.

Penicillin G aqueous (Pfizerpen-G)

Clinical Context:  Intravenous penicillin is first-line antibiotic therapy for severe leptospirosis. Penicillin interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.

Doxycycline (Vibramycin, Doryx, Adoxa, Morgidox, Mondoxyne NL)

Clinical Context:  Doxycycline inhibits protein synthesis, and thus bacterial growth, by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Excretion is hepatobiliary and renal.


Clinical Context:  Ampicillin is a second-line agent or for patients younger than 8 years of age, in whom doxycycline is contraindicated. This agent interferes with synthesis of cell-wall mucopeptides during active multiplication, resulting in bactericidal activity. Excretion is primarily renal, although some ampicillin is metabolized by the liver.

Amoxicillin (Moxatag)

Clinical Context:  Amoxicillin is a second-line agent or for patients younger than 8 years of age, in whom doxycycline is contraindicated. This agent interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.

Erythromycin ethylsuccinate (E.E.S., EryPed, Erythrocin, PCE, Ery-Tab)

Clinical Context:  Erythromycin inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. In pregnant patients who are allergic to penicillin, erythromycin is the therapy of choice.

Cefotaxime (Claforan)

Clinical Context:  A third-generation cephalosporin with broad gram-negative spectrum, cefotaxime has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. This agent arrests bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins, which in turn inhibits bacterial growth.

Ceftriaxone (Rocephin)

Clinical Context:  Ceftriaxone is a third-generation cephalosporin with broad-spectrum, gram-negative activity. It has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms.

Ceftriaxone exerts its bactericidal effect by interfering with the synthesis of peptidoglycan, a major structural component of bacterial cell walls. Bacteria eventually lyse owing to the ongoing activity of cell wall autolytic enzymes while cell wall assembly is arrested.

Ceftriaxone is highly stable in presence of beta-lactamases, both penicillinase and cephalosporinase, produced by gram-negative and gram-positive bacteria. Approximately 33-67% of the dose is excreted unchanged in urine; the remainder is secreted in bile and ultimately in feces as microbiologically inactive compounds.

This agent reversibly binds to human plasma proteins. Binding has been reported to decrease with increasing plasma concentrations of the drug, from 95% bound at plasma concentrations < 25 mcg/mL to 85% bound at 300 mcg/mL.

Class Summary

For severe leptospirosis, intravenous penicillin G has long been considered the drug of choice. Doxycycline is used for the treatment of mild leptospirosis. Ampicillin or amoxicillin are alternatives for the treatment of mild leptospirosis. Erythromycin is the therapy of choice in pregnant patients who are allergic to penicillin. Third-generation cephalosporins have become widely used for intravenous antibiotic treatment in patients with severe leptospirosis.

Methylprednisolone (A-Methapred, Medrol, Depo-Medrol, Solu-Medrol)

Clinical Context:  Methylprednisolone decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability. High-dose pulsed methylprednisolone (30 mg/kg/d, not to exceed 1500 mg) has been used successfully to treat patients with leptospiral renal failure without dialysis.

Class Summary

In patients with leptospirosis, corticosteroids are indicated to improve renal failure outcome.


Sandra G Gompf, MD, FACP, FIDSA, Associate Professor of Infectious Diseases and International Medicine, University of South Florida College of Medicine; Chief, Infectious Diseases Section, Director, Occupational Health and Infection Control Programs, James A Haley Veterans Hospital

Disclosure: Nothing to disclose.


Ana Paula Velez, MD, Assistant Professor of Medicine, Division of Infectious Disease and International Medicine, University of South Florida College of Medicine and James A Haley Veterans Affairs Medical Center; Attending Physician, Moffitt Cancer Center

Disclosure: Nothing to disclose.

Judith Green-McKenzie, MD, MPH, FACP, FACOEM, Associate Professor, Director of Clinical Practice, Occupational Medicine Residency Director, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Disclosure: Nothing to disclose.


Denise Demers, MD, FAAP Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences; Attending Physician, Division of Pediatric Infectious Diseases, Department of Pediatrics, Tripler Army Medical Center

Disclosure: Nothing to disclose.

Juan D Diaz, DO Fellow in Infectious Diseases, University of South Florida College of Medicine, Tampa General Hospital, and James A Haley Veterans Hospital

Disclosure: Nothing to disclose.

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Patrick W Hickey, MD, FAAP Assistant Professor of Pediatrics and Preventive Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Department of Pediatrics, Division of Pediatric Infectious Disease, Walter Reed Army Medical Center

Patrick W Hickey, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, International Society of Travel Medicine, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Edmond A Hooker II, MD, DrPH, FAAEM Assistant Professor, Department of Emergency Medicine, University of Cincinnati College of Medicine; Associate Professor, Department of Health Services Administration, Xavier University

Edmond A Hooker II, MD, DrPH, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Public Health Association, Society for Academic Emergency Medicine, and Southern Medical Association

Disclosure: Nothing to disclose.

Matthew R Jezior, MD Fellow, Department of Cardiology, Walter Reed Medical Center

Disclosure: Nothing to disclose.

Maria D Mileno, MD Associate Professor of Medicine, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University

Maria D Mileno, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, International Society of Travel Medicine, and Sigma Xi

Disclosure: Nothing to disclose.

Joseph T Morris, MD Chief of Infectious Disease Service, Madigan Army Medical Center; Assistant Professor, Department of Internal Medicine, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.

Gary J Noel, MD Professor, Department of Pediatrics, Weill Cornell Medical College; Attending Pediatrician, New York-Presbyterian Hospital

Gary J Noel, MD is a member of the following medical societies: Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Cecily K Peterson, MD Program Director, Clinical Faculty, Department of Medicine, Madigan Army Medical Center

Disclosure: Nothing to disclose.

Charles V Sanders, MD Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine at New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center

Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physician Executives, American College of Physicians, American Federation for Medical Research, American Foundation for AIDS Research, AmericanGeriatricsSociety, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, InfectiousDiseases Societyof America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology

Disclosure: Nothing to disclose.

William H Shoff, MD, DTM&H Director, PENN Travel Medicine; Associate Professor, Department of Emergency Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine

William H Shoff, MD, DTM&H is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Jeter (Jay) Pritchard Taylor III, MD Compliance Officer, Attending Physician, Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Health Richland, University of South Carolina School of Medicine; Medical Director, Department of Emergency Medicine, Palmetto Health Baptist

Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.


  1. Palaniappan RU, Ramanujam S, Chang YF. Leptospirosis: pathogenesis, immunity, and diagnosis. Curr Opin Infect Dis. 2007 Jun. 20(3):284-92. [View Abstract]
  2. Yang CW. Leptospirosis in Taiwan--an underestimated infectious disease. Chang Gung Med J. 2007 Mar-Apr. 30(2):109-15. [View Abstract]
  3. Githeko AK, Lindsay SW, Confalonieri UE, Patz JA. Climate change and vector-borne diseases: a regional analysis. Bull World Health Organ. 2000. 78(9):1136-47. [View Abstract]
  4. National Research Council. Advancing the Science of Climate Change. Washington, DC: The National Academies Press; 2010.
  5. CDC. From the Centers for Disease Control and Prevention. Update: outbreak of acute febrile illness among athletes participating in Eco-Challenge-Sabah 2000--Borneo, Malaysia, 2000. JAMA. 2001 Feb 14. 285(6):728-30. [View Abstract]
  6. CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998 Aug 21. 47(32):673-6. [View Abstract]
  7. CDC. Outbreak of leptospirosis among white-water rafters--Costa Rica, 1996. MMWR Morb Mortal Wkly Rep. 1997 Jun 27. 46(25):577-9. [View Abstract]
  8. Radl C, Müller M, Revilla-Fernandez S, Karner-Zuser S, de Martin A, Schauer U, et al. Outbreak of leptospirosis among triathlon participants in Langau, Austria, 2010. Wien Klin Wochenschr. 2011 Dec. 123(23-24):751-5. [View Abstract]
  9. CDC. From the Centers for Disease Control and Prevention. Outbreak of acute febrile illness and pulmonary hemorrhage--Nicaragua, 1995. JAMA. 1995 Dec 6. 274(21):1668. [View Abstract]
  10. Gaynor K, Katz AR, Park SY, Nakata M, Clark TA, Effler PV. Leptospirosis on Oahu: an outbreak associated with flooding of a university campus. Am J Trop Med Hyg. 2007 May. 76(5):882-5. [View Abstract]
  11. Socolovschi C, Angelakis E, Renvoisé A, Fournier PE, Marié JL, Davoust B, et al. Strikes, flooding, rats, and leptospirosis in Marseille, France. Int J Infect Dis. 2011 Oct. 15(10):e710-5. [View Abstract]
  12. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001 Apr. 14(2):296-326. [View Abstract]
  13. Inada R, Ido Y, Hoki R. The etiology, mode of infection, and specific therapy of Weil's disease (spirochaetosis icterohaemorrhagica. J Exper Med. 1916. 23:377-402.
  14. GILLESPIE RW, RYNO J. Epidemiology of leptospirosis. Am J Public Health Nations Health. 1963 Jun. 53:950-5. [View Abstract]
  15. Heisey GB, Nimmanitya S, Karnchanachetanee C, Tingpalapong M, Samransamruajkit S, Hansukjariya P, et al. Epidemiology and characterization of leptospirosis at an urban and provincial site in Thailand. Southeast Asian J Trop Med Public Health. 1988 Jun. 19(2):317-22. [View Abstract]
  16. SMITH DJ, SELF HR. Observations on the survival of Leptospira australis A in soil and water. J Hyg (Lond). 1955 Dec. 53(4):436-44. [View Abstract]
  17. Cacciapuoti B, Ciceroni L, Maffei C, Di Stanislao F, Strusi P, Calegari L, et al. A waterborne outbreak of leptospirosis. Am J Epidemiol. 1987 Sep. 126(3):535-45. [View Abstract]
  18. Chakurkar G, Vaideeswar P, Pandit SP, Divate SA. Cardiovascular lesions in leptospirosis: an autopsy study. J Infect. 2008 Mar. 56(3):197-203. [View Abstract]
  19. Chierakul W, Tientadakul P, Suputtamongkol Y, Wuthiekanun V, Phimda K, Limpaiboon R, et al. Activation of the coagulation cascade in patients with leptospirosis. Clin Infect Dis. 2008 Jan 15. 46(2):254-60. [View Abstract]
  20. Wagenaar JF, Goris MG, Sakundarno MS, Gasem MH, Mairuhu AT, de Kruif MD, et al. What role do coagulation disorders play in the pathogenesis of leptospirosis?. Trop Med Int Health. 2007 Jan. 12(1):111-22. [View Abstract]
  21. Smythe L, Adler B, Hartskeerl RA, Galloway RL, Turenne CY, Levett PN. Classification of Leptospira genomospecies 1, 3, 4 and 5 as Leptospira alstonii sp. nov., Leptospira vanthielii sp. nov., Leptospira terpstrae sp. nov. and Leptospira yanagawae sp. nov., respectively. Int J Syst Evol Microbiol. 2013 May. 63:1859-62. [View Abstract]
  22. US Department of Health and Human Services. Summary of notifiable diseases, United States 1995. MMWR Morb Mortal Wkly Rep. 1996 Oct 25. 44(53):1-87. [View Abstract]
  23. Malani J, Pryor J, Lusangulira K. Leptospirosis in Pohnpei (1986-1995): a case series on the use of dopamine/steroid for Weil's syndrome. Pacific Health Dialog. 1996. 3:153-61.
  24. Sasaki DM, Pang L, Minette HP, Wakida CK, Fujimoto WJ, Manea SJ, et al. Active surveillance and risk factors for leptospirosis in Hawaii. Am J Trop Med Hyg. 1993 Jan. 48(1):35-43. [View Abstract]
  25. Katz AR, Buchholz AE, Hinson K, Park SY, Effler PV. Leptospirosis in Hawaii, USA, 1999-2008. Emerg Infect Dis. 2011 Feb. 17(2):221-6. [View Abstract]
  26. Demers RY, Thiermann A, Demers P, Frank R. Exposure to Leptospira icterohaemorrhagiae in inner-city and suburban children: a serologic comparison. J Fam Pract. 1983 Dec. 17(6):1007-11. [View Abstract]
  27. Childs JE, Schwartz BS, Ksiazek TG, Graham RR, LeDuc JW, Glass GE. Risk factors associated with antibodies to leptospires in inner-city residents of Baltimore: a protective role for cats. Am J Public Health. 1992 Apr. 82(4):597-9. [View Abstract]
  28. Trevejo RT, Rigau-Pérez JG, Ashford DA, McClure EM, Jarquín-González C, Amador JJ, et al. Epidemic leptospirosis associated with pulmonary hemorrhage-Nicaragua, 1995. J Infect Dis. 1998 Nov. 178(5):1457-63. [View Abstract]
  29. Jackson LA, Kaufmann AF, Adams WG, Phelps MB, Andreasen C, Langkop CW, et al. Outbreak of leptospirosis associated with swimming. Pediatr Infect Dis J. 1993 Jan. 12(1):48-54. [View Abstract]
  30. Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CR. Pathology and pathophysiology of pulmonary manifestations in leptospirosis. Braz J Infect Dis. 2007 Feb. 11(1):142-8. [View Abstract]
  31. Dall'Antonia M, Sluga G, Whitfield S, Teall A, Wilson P, Krahé D. Leptospirosis pulmonary haemorrhage: a diagnostic challenge. Emerg Med J. 2008 Jan. 25(1):51-2. [View Abstract]
  32. Shaked Y, Shpilberg O, Samra D, Samra Y. Leptospirosis in pregnancy and its effect on the fetus: case report and review. Clin Infect Dis. 1993 Aug. 17(2):241-3. [View Abstract]
  33. Hawaii Dept of Health. Communicable Disease Surveillance. Hawaii: Communicable Disease Report. Nov/Dec 1999. 15.
  34. El Bouazzaoui A, Houari N, Arika A, Belhoucine I, Boukatta B, Sbai H, et al. Facial palsy associated with leptospirosis. Eur Ann Otorhinolaryngol Head Neck Dis. 2011 Nov. 128(5):275-7. [View Abstract]
  35. Peter G, Narasimha H. Acalculous cholecystitis: a rare presentation of leptospirosis progressing to Weil's disease. Asian Pac J Trop Med. 2011 Dec. 4(12):1007-8. [View Abstract]
  36. Pappachan JM, Mathew S, Thomas B, Renjini K, Scaria CK, Shukla J. The incidence and clinical characteristics of the immune phase eye disease in treated cases of human leptospirosis. Indian J Med Sci. 2007 Aug. 61(8):441-7. [View Abstract]
  37. Person DA, Burnett MW. Leptospirosis. Tripler Army Medical Center. Medical Surveillance Monthly Report. 1996. 2:7-8.
  38. Person DA. Leptospirosis in the Pacific. : ;:. Tripler Army Medical Center. Medical Surveillance Monthly Report. 1998. 4:12-14.
  39. Spichler A, Spichler E, Moock M, Vinetz JM, Leake JA. Acute pancreatitis in fatal anicteric leptospirosis. Am J Trop Med Hyg. 2007 May. 76(5):886-7. [View Abstract]
  40. World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. Available at http://whqlibdoc.who.int/hq/2003/WHO_CDS_CSR_EPH_2002.23.pdf. Accessed: April 24, 2014.
  41. Vasconcellos FA, Coutinho ML, da Silva EF, Fernandes CP, Monte LG, Seyffert N, et al. Testing different antigen capture ELISA formats for detection of Leptospira spp. in human blood serum. Trans R Soc Trop Med Hyg. 2010 Apr. 104(4):259-64. [View Abstract]
  42. Brett-Major DM, Coldren R. Antibiotics for leptospirosis. Cochrane Database Syst Rev. 2012 Feb 15. 2:CD008264. [View Abstract]
  43. Watt G, Padre LP, Tuazon ML, Calubaquib C, Santiago E, Ranoa CP, et al. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet. 1988 Feb 27. 1(8583):433-5. [View Abstract]
  44. Costa E, Lopes AA, Sacramento E, Costa YA, Matos ED, Lopes MB, et al. Penicillin at the late stage of leptospirosis: a randomized controlled trial. Rev Inst Med Trop Sao Paulo. 2003 May-Jun. 45(3):141-5. [View Abstract]
  45. Murray CK, Hospenthal DR. Determination of susceptibilities of 26 Leptospira sp. serovars to 24 antimicrobial agents by a broth microdilution technique. Antimicrob Agents Chemother. 2004 Oct. 48(10):4002-5. [View Abstract]
  46. Dursun B, Bostan F, Artac M, Varan HI, Suleymanlar G. Severe pulmonary haemorrhage accompanying hepatorenal failure in fulminant leptospirosis. Int J Clin Pract. 2007 Jan. 61(1):164-7. [View Abstract]
  47. Shenoy VV, Nagar VS, Chowdhury AA, Bhalgat PS, Juvale NI. Pulmonary leptospirosis: an excellent response to bolus methylprednisolone. Postgrad Med J. 2006 Sep. 82(971):602-6. [View Abstract]
  48. Meaudre E, Asencio Y, Montcriol A, Martinaud C, Graffin B, Palmier B, et al. [Immunomodulation in severe leptospirosis with multiple organ failure: plasma exchange, intravenous immunoglobulin or corticosteroids?]. Ann Fr Anesth Reanim. 2008 Feb. 27(2):172-6. [View Abstract]
  49. Rodrigo C, Lakshitha de Silva N, Goonaratne R, Samarasekara K, Wijesinghe I, Parththipan B, et al. High dose corticosteroids in severe leptospirosis: a systematic review. Trans R Soc Trop Med Hyg. 2014 Dec. 108 (12):743-50. [View Abstract]
  50. Trivedi SV, Chavda RK, Wadia PZ, Sheth V, Bhagade PN, Trivedi SP, et al. The role of glucocorticoid pulse therapy in pulmonary involvement in leptospirosis. J Assoc Physicians India. 2001 Sep. 49:901-3. [View Abstract]
  51. Martins MG, Matos KT, da Silva MV, de Abreu MT. Ocular manifestations in the acute phase of leptospirosis. Ocul Immunol Inflamm. 1998 Jun. 6(2):75-9. [View Abstract]
  52. Takafuji ET, Kirkpatrick JW, Miller RN, Karwacki JJ, Kelley PW, Gray MR, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med. 1984 Feb 23. 310(8):497-500. [View Abstract]
  53. [Guideline] Guidugli F, Castro AA, Atallah AN. Antibiotics for preventing leptospirosis. Cochrane Database Syst Rev. 2000. CD001305. [View Abstract]
  54. Agampodi SB, Matthias MA, Moreno AC, Vinetz JM. Utility of quantitative polymerase chain reaction in leptospirosis diagnosis: association of level of leptospiremia and clinical manifestations in Sri Lanka. Clin Infect Dis. 2012 May. 54(9):1249-55. [View Abstract]
  55. AREAN VM. The pathologic anatomy and pathogenesis of fatal human leptospirosis (Weil's disease). Am J Pathol. 1962 Apr. 40:393-423. [View Abstract]
  56. Barkin RM, Guckian JC, Glosser JW. Infection by leptospira ballum: a laboratory-associated case. South Med J. 1974 Feb. 67(2):155 passim. [View Abstract]
  57. Everard CO, Bennett S, Edwards CN, Nicholson GD, Hassell TA, Carrington DG, et al. An investigation of some risk factors for severe leptospirosis on Barbados. J Trop Med Hyg. 1992 Feb. 95(1):13-22. [View Abstract]
  58. Gaspari R, Annetta MG, Cavaliere F, Pallavicini F, Grillo R, Conti G, et al. Unusual presentation of leptospirosis in the late stage of pregnancy. Minerva Anestesiol. 2007 Jul-Aug. 73(7-8):429-32. [View Abstract]
  59. Harris BM, Blatz PJ, Hinkle MK, McCall S, Beckius ML, Mende K, et al. In vitro and in vivo activity of first generation cephalosporins against Leptospira. Am J Trop Med Hyg. 2011 Nov. 85(5):905-8. [View Abstract]
  60. Katz AR, Manea SJ, Sasaki DM. Leptospirosis on Kauai: investigation of a common source waterborne outbreak. Am J Public Health. 1991 Oct. 81(10):1310-2. [View Abstract]
  61. Khositseth S, Sudjaritjan N, Tananchai P, Ong-ajyuth S, Sitprija V, Thongboonkerd V. Renal magnesium wasting and tubular dysfunction in leptospirosis. Nephrol Dial Transplant. 2008 Mar. 23(3):952-8. [View Abstract]
  62. Khosravi M, Bastani B. Acute renal failure due to leptospirosis in a renal transplant recipient: a brief review of the literature. Transplant Proc. 2007 May. 39(4):1263-6. [View Abstract]
  63. Lettieri C, Moon J, Hickey P, Gray M, Berg B, Hospenthal D. Prevalence of leptospira antibodies in U.S. Army blood bank donors in Hawaii. Mil Med. 2004 Sep. 169(9):687-90. [View Abstract]
  64. Musgrave JE, Person DA. Acute renal failure in children due to leptospirosis. Pac Health Dialog. 1996. 3:200-1.
  65. Phimda K, Hoontrakul S, Suttinont C, Chareonwat S, Losuwanaluk K, Chueasuwanchai S, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother. 2007 Sep. 51(9):3259-63. [View Abstract]
  66. Wang Z, Jin L, Wegrzyn A. Leptospirosis vaccines. Microb Cell Fact. 2007 Dec 11. 6:39. [View Abstract]
  67. Watt G, Padre LP, Tuazon M, Calubaquib C. Skeletal and cardiac muscle involvement in severe, late leptospirosis. J Infect Dis. 1990 Jul. 162(1):266-9. [View Abstract]

A scanning electron micrograph depicting Leptospira atop a 0.1-µm polycarbonate filter. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Centers for Disease Control/Rob Weyant)

A scanning electron micrograph depicting Leptospira atop a 0.1-µm polycarbonate filter. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Centers for Disease Control/Rob Weyant)

Silver stain, liver, fatal human leptospirosis. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Centers for Disease Control/Dr. Martin Hicklin)

Darkfield microscopy of leptospiral microscopic agglutination test. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Centers for Disease Control/Mrs. M. Gatton)

A scanning electron micrograph depicting Leptospira atop a 0.1-µm polycarbonate filter. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Centers for Disease Control/Rob Weyant)

Silver stain, liver, fatal human leptospirosis. (This image is in the public domain and thus free of any copyright restrictions. Courtesy of the Centers for Disease Control/Dr. Martin Hicklin)